Pharmaron-backed Zentalis Pharmaceuticals has now secured $147m altogether and will advance its breast cancer and solid tumour candidates through clinical trials.
Zentalis Pharmaceuticals, a US-based small molecule therapeutics developer backed by contract research firm Pharmaron, closed an $85m series C round yesterday.
The round included Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Eventide Asset Management and Surveyor Capital, a division of asset manager Citadel.
Founded in 2014, Zentalis oversees a pipeline of drug candidates to treat breast cancer and solid tumours, the advancement of which will be supported by the series C funding.
The company’s lead candidate,…
